Search Results - "Heukamp, L."

Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation by Sprüssel, A, Schulte, J H, Weber, S, Necke, M, Händschke, K, Thor, T, Pajtler, K W, Schramm, A, König, K, Diehl, L, Mestdagh, P, Vandesompele, J, Speleman, F, Jastrow, H, Heukamp, L C, Schüle, R, Dührsen, U, Buettner, R, Eggert, A, Göthert, J R

“…Lysine (K)-specific demethylase 1A (LSD1/KDM1A) has been identified as a potential therapeutic target in solid cancers and more recently in acute myeloid…”
Get full text

MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells by Schulte, J H, Lindner, S, Bohrer, A, Maurer, J, De Preter, K, Lefever, S, Heukamp, L, Schulte, S, Molenaar, J, Versteeg, R, Thor, T, Künkele, A, Vandesompele, J, Speleman, F, Schorle, H, Eggert, A, Schramm, A

“…Neuroblastoma is an embryonal tumor with a heterogeneous clinical course. The tumor is presumed to be derived from the neural crest, but the cells of origin…”
Get full text

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies by Althoff, K, Beckers, A, Bell, E, Nortmeyer, M, Thor, T, Sprüssel, A, Lindner, S, De Preter, K, Florin, A, Heukamp, L C, Klein-Hitpass, L, Astrahantseff, K, Kumps, C, Speleman, F, Eggert, A, Westermann, F, Schramm, A, Schulte, J H

“…Neuroblastoma, a childhood cancer that originates from neural crest-derived cells, is the most common deadly solid tumor of infancy. Amplification of the MYCN…”
Get full text

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing by Christopoulos, P., Kirchner, M., Roeper, J., Saalfeld, F., Janning, M., Bozorgmehr, F., Magios, N., Kazdal, D., Volckmar, A.L., Brückner, L.M., Bochtler, T., Kriegsmann, M., Endris, V., Penzel, R., Kriegsmann, K., Eichhorn, M., Herth, F.J.F., Heussel, C.P., El Shafie, R.A., Schneider, M.A., Muley, T., Meister, M., Faehling, M., Fischer, J.R., Heukamp, L., Schirmacher, P., Bischoff, H., Wermke, M., Loges, S., Griesinger, F., Stenzinger, A., Thomas, M.

“…•EGFR variant, TP53 and brain status together predict survival in EGFR+ NSCLC (ENS).•Co-mutations beyond TP53 are rare and their clinical significance remains…”
Get full text

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib by Bos, M, Gardizi, M, Schildhaus, H.U, Heukamp, L.C, Geist, T, Kaminsky, B, Zander, T, Nogova, L, Scheffler, M, Dietlein, M, Kobe, C, Holstein, A, Maintz, D, Büttner, R, Wolf, J

“…Abstract A 55-year-old Caucasian woman with lung adenocarcinoma stage IV presented with repeated relapse after treatment with cytotoxic chemotherapy…”
Get full text

Hybrid capture NGS reliably detects a spectrum of clinically significant genetic aberrations in both, primary diagnostics and the relapse scenario by Schatz, S., Falk, M., Menon, R., Heukamp, L.C., Roeper, J., Griesinger, F., Tiemann, M.

Get full text

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors by Wagener-Ryczek, S., Heydt, C., Sueptitz, J., Michels, S., Falk, M., Alidousty, C., Fassunke, J., Tiemann, M., Heukamp, L., Wolf, J., Buettner, R., Merkelbach-Bruse, S.

Get full text

Combined PET/MRI: Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tübingen, Germany by Bailey, D. L., Pichler, B. J., Gückel, B., Antoch, G., Barthel, H., Bhujwalla, Z. M., Biskup, S., Biswal, S., Bitzer, M., Boellaard, R., Braren, R. F., Brendle, C., Brindle, K., Chiti, A., la Fougère, C., Gillies, R., Goh, V., Goyen, M., Hacker, M., Heukamp, L., Knudsen, G. M., Krackhardt, A. M., Law, I., Morris, J. C., Nikolaou, K., Nuyts, J., Ordonez, A. A., Pantel, K., Quick, H. H., Riklund, K., Sabri, O., Sattler, B., Troost, E. G. C., Zaiss, M., Zender, L., Beyer, Thomas

“…The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in Tübingen, Germany, from…”
Get full text

Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors by Ramdani, H.O., Falk, M., Heukamp, L.C., Schatz, S., Tiemann, M., Wesseler, C., Diehl, L., Schuuring, E., Groen, H.J.M., Griesinger, F.

“…Immune related endonucleases have recently been described as potential therapeutic targets and predictors of response to treatment with immune checkpoint…”
Get full text

Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients by Roeper, J., Lueers, A.C., Falk, M., Schatz, S., Tiemann, M., Wesseler, C., Wiest, G.H., Sackmann, S., Ukena, D., Heukamp, L., Griesinger, F.

Get full text

Risk of not receiving second-line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts by Roeper, J., Falk, M., Schatz, S., Tiemann, M., Wesseler, C., Wiest, G., Sackmann, S., Ukena, D., Heukamp, L.C., Griesinger, F.

Get full text

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib by Thunnissen, E., Lissenberg-Witte, B.I., van den Heuvel, M.M., Monkhorst, K., Skov, B.G., Sørensen, J.B., Mellemgaard, A., Dingemans, A.M.C., Speel, E.J.M., de Langen, A.J., Hashemi, S.M.S., Bahce, I., van der Drift, M.A., Looijen-Salamon, M.G., Gosney, J., Postmus, P.E., Samii, S.M.S., Duplaquet, F, Weynand, B., Durando, X., Penault-Llorca, F., Finn, S., Grady, A.O, Oz, B., Akyurek, N., Buettner, R., Wolf, J., Bubendorf, L., Duin, S., Marondel, I., Heukamp, L.C., Timens, W., Schuuring, E.M.D., Pauwels, P., Smit, E.F.

“…•Discordant ALK immunohistochemistry positive (IHC) FISH negative NSCLC occurs at low frequency.•Not all locally performed ALK IHC and FISH test were centrally…”
Get full text

TCam-2 but not JKT-1 cells resemble seminoma in cell culture by Eckert, D., Nettersheim, D., Heukamp, L. C., Kitazawa, S., Biermann, K., Schorle, H.

“…Of all malignancies diagnosed in men between 17 and 45 years of age, 60% are germ cell tumors (GCT). GCT arise from carcinoma in situ cells, which are thought…”
Get full text

Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma by Rosoux, A, Pauwels, P, Duplaquet, F, D’Haene, N, Weynand, B, Delos, M, Menon, R, Heukamp, L.C, Thunnissen, E, Ocak, S

“…Highlights • Effectiveness of crizotinib in an ALK IHC-positive/FISH-negative stage IV NSCLC. • Importance of IHC when dealing with ALK FISH-borderline cases…”
Get full text

Targeted Therapy for Neuroblastoma: ALK Inhibitors by Schulte, J H, Schulte, S, Heukamp, L C, Astrahantseff, K, Stephan, H, Fischer, M, Schramm, A, Eggert, A

“…Treatment for neuroblastoma, the most common extracranial childhood tumor, spans a broad range of aggressiveness that mirrors the risk profiles of disease…”
Get more information

Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay by Menon, R, Mueller, J, Lakis, S, Hube, A, Bochtler, T, Wesseler, C, Griesinger, F, Loeffler, H, Langenbuch, T, Brandts, C, Garcia, A.P, Krämer, A, Heuckmann, J, Heukamp, L

“…An abstract of a study by Menon et al analyzing identification of therapeutically targetable genomic alterations in a cohort of patients with carcinomas of…”
Get full text

Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma by Friedrichs, N, Küchler, J, Endl, E, Koch, A, Czerwitzki, J, Wurst, P, Metzger, D, Schulte, JH, Holst, MI, Heukamp, LC, Larsson, O, Tanaka, S, Kawai, A, Wardelmann, E, Buettner, R, Pietsch, T, Hartmann, W

“…Synovial sarcomas account for 5-10% of all soft tissue sarcomas and the majority of synovial sarcomas display characteristic t(X;18) translocations that result…”
Get full text

IKKε/IKBKE integrates LPS and IL-17A signaling cascades to establish an inflammatory microenvironment in intestinal tumors by Goktuna, S, Shostak, K, Chau, T.L, Heukamp, L, Close, P, Rahmouni, S, Van Loo, G, Buttner, R, Greten, F, Chariot, A

Get full text

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas by Künkele, Annette, De Preter, Katleen, Heukamp, Lukas, Thor, Theresa, Pajtler, Kristian W, Hartmann, Wolfgang, Mittelbronn, Michel, Grotzer, Michael A, Deubzer, Hedwig E, Speleman, Frank, Schramm, Alexander, Eggert, Angelika, Schulte, Johannes H

“…Medulloblastomas account for 20% of pediatric brain tumors. With an overall survival of 40%-70%, their treatment is still a challenge. The majority of…”
Get full text

Insulin-like growth factor-I receptor acts as a growth regulator in synovial sarcoma by FRIEDRICHS, N, OCHLER, K, LARSSON, O, TANAKA, S, KAWAI, A, WARDELMANN, E, BUETTNER, R, PIETSCH, T, HARTMANN, W, ENDL, E, KOCH, A, CZERWITZKI, J, WURST, P, TIETZGER, D, SCHULTE, J. H, HOST, M. I, HEUKAMP, L. C

Get full text